Comparison of the Efficacy and Safety of Memantal and the Original Drug Memantine in Mild and Moderate Alzheimer’s Disease-Associated Dementia

Objective. To carry out a comparative assessment of the clinical efficacy and safety of the original drug memantine and the generic drug (memantal) in patients with mild and moderate dementia in Alzheimer's disease (AD). Materials and methods. A randomized, controlled, comparative study was performed over a period of six months in 50 patients with mild or moderate AD-associated dementia who had not previously received acetylcholinesterase inhibitors or memantine. The original memantine and memantal were prescribed at a starting dose of 5 mg/day, after which the dose was titrated in accordance with the manufacturer's recommendations. Patients' status was evaluated using the MMSE scale, the Cummings NPI questionnaire, and the IADL questionnaire, and side effects were recorded. Results and conclusions. There were no significant differences in the actions of memantal and the original memantine in relation to measures of cognitive functioning, behavioral or psychotic symptoms, or operant activity, and there were no differences in safety. Both study drugs evoked minor improvements in cognitive functions, which were more marked in patients with mild AD-associated dementia than in those with late-onset AD. These results lead to the conclusion that there are no significant differences in the efficacy and safety of the generic (memantal) and the original memantine in patients with mild and moderate AD-associated dementia.

from Physiology via xlomafota13 on Inoreader http://ift.tt/2eIMgaH
via IFTTT